Therapeutic Asset Ratings
409 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Nrm-823
Ovarian Cancer
Normunity AccelCo, Inc.
P1
C
(36)
Nuv-868
Ovarian Cancer
Nuvation Bio Inc.
P1
C
(36)
nxp800
Ovarian Cancer
Nuvectis Pharma, Inc.
P1
C
(36)
Obinutuzumab
Ovarian Cancer
NeoTX Therapeutics Ltd.
P1
C
(36)
OPB-201
Ovarian Cancer
Outpace Bio, Inc.
P1
C
(36)
Ovm-200
Ovarian Cancer
Oxford Vacmedix UK Ltd.
P1
C
(36)
Pcna Inhibitor Aoh1996
Ovarian Cancer
City of Hope Medical Center
P1
C
(36)
pf-07224826
Ovarian Cancer
Pfizer
P1
C
(36)
pf-07263689
Ovarian Cancer
Pfizer
P1
C
(36)
Phn-010
Ovarian Cancer
Pheon Therapeutics
P1
C
(36)
Phst001
Ovarian Cancer
Pheast Therapeutics
P1
C
(36)
PITTSBURGH COMPOUND B UNLABELLED
Ovarian Cancer
University of Alabama at Birmingham
P1
C
(36)
P-Muc1C-Allo1 Car-T Cells
Ovarian Cancer
Poseida Therapeutics, Inc.
P1
C
(36)
QXL138AM
Ovarian Cancer
Nammi Therapeutics Inc
P1
C
(36)
rad301
Ovarian Cancer
Radiopharm Theranostics, Ltd
P1
C
(36)
Rgt-490
Ovarian Cancer
Regor Pharmaceuticals Inc.
P1
C
(36)
Rimiducid
Ovarian Cancer
Poseida Therapeutics, Inc.
P1
C
(36)
Sct-001 Car-T Cells
Ovarian Cancer
Shanghai Gynecologic Oncology Group
P1
C
(36)
Slv-154
Ovarian Cancer
Solve Therapeutics
P1
C
(36)
Son-Dp
Ovarian Cancer
Qurgen Inc.
P1
C
(36)
syn608
Ovarian Cancer
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
P1
C
(36)
syn818
Ovarian Cancer
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
P1
C
(36)
Synkir-110, Autologous T Cells Transduced With Mesothelin Kir-Car
Ovarian Cancer
Verismo Therapeutics
P1
C
(36)
sys6043
Ovarian Cancer
Conjupro Biotherapeutics, Inc.
P1
C
(36)
Tbi-1301
Ovarian Cancer
University Health Network, Toronto
P1
C
(36)
Showing 351 to 375 of 409 assets
Previous
Page 15 of 17
Next